{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:42:56Z","timestamp":1785224576071,"version":"3.55.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy. However, these therapies commonly precipitate immune-related adverse events, with thyroid dysfunction being the most frequent manifestation of endocrine toxicity. Whether subclinical abnormal baseline thyroid function (sABTF) predisposes to overt thyroid dysfunction during ICI therapy\u2014and if so, how it influences time-to-onset, phenotype, severity, and clinical decision have not been fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 235 patients with cancer who underwent ICI therapy at Peking University Cancer Hospital between January 1, 2018, and September 30, 2024. Patients were stratified by baseline thyroid function status and monitored for ICI-induced overt thyroid dysfunction. Multivariate logistic regression analysis identified the risk factors for overt thyroid dysfunction. To examine baseline free thyroxine (FT4) cutoff, we used restricted cubic splines and receiver operating characteristic (ROC) analysis. Time-to-event was estimated using Kaplan-Meier curves and multivariate Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 99 patients with sABTF, 51.52% developed overt thyroid dysfunction during ICI therapy. Baseline FT4 was associated with overt hypothyroidism (adjusted odds ratio [OR], 0.88; 95% confidence interval [CI], 0.78\u20130.99;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.037). A data-driven FT4 threshold of 13.91 pmol\/L showed moderate discrimination (area under the ROC curve, 0.687). Using this threshold, higher FT4 (\u226513.91 pmol\/L) was associated with substantially lower odds of overt hypothyroidism (adjusted OR, 0.17; 95% CI, 0.06\u20130.47;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001), indicating that patients with FT4 &amp;lt;13.91 pmol\/L were at markedly elevated risk. Severe subclinical hypothyroidism at baseline (TSH \u226510 mIU\/L) was associated with a shorter time to overt hypothyroidism (median 7.78 weeks; adjusted hazard ratio [HR], 2.84; 95% CI, 1.42\u20135.67;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003), with the highest risk observed among patients who also had FT4 &amp;lt;13.91 pmol\/L (median 6.57 weeks; adjusted HR, 10.05; 95% CI, 3.13\u201332.23;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre-existing thyroid abnormalities, particularly severe subclinical hypothyroidism with concurrent FT4 &amp;lt;13.91 pmol\/L, identify a high-risk subgroup prone to an earlier onset of ICI-induced overt hypothyroidism. These data support comprehensive baseline assessments and intensified early monitoring to enable timely detection and management during ICI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1690196","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:15Z","timestamp":1762751895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pre-existing subclinical hypothyroidism and low free thyroxine in patients undergoing immune checkpoint inhibitor therapies is a risk factor for overt hypothyroidism"],"prefix":"10.3389","volume":"16","author":[{"given":"Yu","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113949","article-title":"Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study","volume":"202","author":"Kennedy","year":"2024","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0375","article-title":"Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment","volume":"23","author":"Patel","year":"2018","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03151-2","article-title":"Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors","volume":"71","author":"von Itzstein","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC202007070","article-title":"Hypothyroidism","volume":"173","author":"McDermott","year":"2020","journal-title":"Ann Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000356507","article-title":"2013 ETA guideline: management of subclinical hypothyroidism","volume":"2","author":"Pearce","year":"2013","journal-title":"Eur Thyroid J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03323-9","article-title":"Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study","volume":"81","author":"Wu","year":"2023","journal-title":"Endocrine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy","volume":"44","author":"Luongo","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy","volume":"44","author":"Brilli","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e240101","DOI":"10.1530\/ERC-24-0101","article-title":"Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center","volume":"31","author":"Barlas","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac467","article-title":"Elevated TSH level, TgAb, and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 blockade","volume":"107","author":"Kobayashi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad231","article-title":"Risk of Thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline","volume":"108","author":"Zhou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semcancer.2020.12.008","article-title":"Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism","volume":"79","author":"Basolo","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad260","article-title":"Clinical characters and influence factors of immune checkpoint inhibitor-related thyroid dysfunction","volume":"108","author":"Zhang","year":"2023","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1690196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:15Z","timestamp":1762751895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1690196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":20,"alternative-id":["10.3389\/fendo.2025.1690196"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1690196","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1690196"}}